Edgar Engleman

Clinical Focus

• Pathology
• Pathology and Laboratory Medicine

Professional Education

Postdoctoral Advisees

Maria Caimol , Juliana Gaitan , Megan Suhoski , Daniel Winer

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information

Research Interests

The goal of this laboratory is to better understand dendritic cell biology with the objective of using this information to discover and develop more effective immunotherapeutic approaches to disease. We pursue this goal by performing experiments in both mice and humans. In our initial clinical studies antigen pulsed dendritic cells were administered to patients with cancer or life-threatening viral infections in order to induce specific immunity. The results of these trials have been extremely encouraging. More recently we have focused our studies on the development and life cycle of dendritic cells, including Langerhans cells, and the results have not only shed new light on dendritic cell biology but also have led to our ability to target dendritic cells in vivo without having to manipulate these cells in vitro. We believe that this new approach will eventually make it possible to downregulate as well as upregulate the immune system in an antigen specific manner.

Clinical Trials

• Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer Completed
• Mixed Chimera Allo Transplantation in Multiple Myeloma No longer recruiting

Publications

• T-cell activation by antigen-loaded pH-sensitive hydrogel particles in vivo: the effect of particle size. Cohen JA, Beaudette TT, Tseng WW, Bachelder EM, Mende I, Engleman EG, Fréchet JM. Bioconjug Chem. 2009; 20 (1): 111-9
• Plasmacytoid dendritic cells take up opsonized antigen leading to CD4+ and CD8+ T cell activation in vivo. Björck P, Beilhack A, Herman EI, Negrin RS, Engleman EG. J Immunol. 2008; 181 (6): 3811-7
• Tolerance and chimerism after renal and hematopoietic-cell transplantation. Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Millan MT, Shizuru JA, Hoppe RT, Lowsky R, Engleman EG, Strober S. N Engl J Med. 2008; 358 (4): 362-8
• Incorporation of CpG oligonucleotide ligand into protein-loaded particle vaccines promotes antigen-specific CD8 T-cell immunity. Standley SM, Mende I, Goh SL, Kwon YJ, Beaudette TT, Engleman EG, Fréchet JM. Bioconjug Chem. 2007 Jan-Feb; 18 (1): 77-83
• Natural killer cells trigger differentiation of monocytes into dendritic cells. Zhang AL, Colmenero P, Purath U, Teixeira de Matos C, Hueber W, Klareskog L, Tarner IH, Engleman EG, Söderström K. Blood. 2007; 110 (7): 2484-93